Work

Clostridioides difficile Infection Management Optimization in Solid Organ Transplant Recipients

Year: 2025

Type: article

Abstract: Purpose: Fidaxomicin (FM) is the preferred therapy for initial and subsequent Clostridioides difficile infection (CDI) episodes due to its potential to reduce recurrence rates compared to vancomycin (VM). In December 2023, a solid organ transplant (SOT) CDI treatment/prophylaxis guideline was developed. The guidance recommends extended-pulsed FM for mild/moderate cases, standard FM for severe non-fulminant cases, and VM prophylaxis for patients receiving antibiotics with a CDI episode in the past 6 months without fecal microbiota transplant (FMT).

Source: American Journal of Transplantation

DOI: 10.1016/j.ajt.2025.07.774

Authors: H. Reynolds, M. Hudson, D. Ilges, C. Votruba, K. Reininger, J. Chacko, R. Corey, H. Vikram

Language: English

Topic: Clostridium difficile and Clostridium perfringens research

Subfield: Infectious Diseases

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $4,300

OpenAlex ID: W4412851755

FWCI:

Cites:

Cited by:

Related to: 10